Examples of using Staphylococcus spp in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Escherichia coli and Staphylococcus spp.
Staphylococcus spp.≤ 1 µg/ ml for susceptible,> 1 µg/ ml for resistant;
Noroxin is active against Staphylococcus spp.
Pathogens such as Staphylococcus spp, E. coli and Proteus mirabilis.
Is used for all members of a genus, e.g. Staphylococcus spp.
Pleuropneumoniae and Staphylococcus spp. Enrofloxacin injection is for intramuscular intravenous and.
It shows activity against gram-positive bacteria: Staphylococcus spp.
In cats,relevant susceptible micro-organisms are E. coli, Staphylococcus spp., Pasteurella spp., Proteus spp. and Klebsiella spp. MIC≤ 0.5 µg ibafloxacin/ml.
Upper respiratory tractinfections caused by susceptible pathogens such as Staphylococcus spp.
In cats,relevant susceptible micro-organisms are E. coli, Staphylococcus spp., Pasteurella spp., Proteus spp. and Klebsiella spp. .
Gram Positive Aerobes Enterococcus faecalis*$Staphylococcus aureus(methicillin susceptible strains only)*^ Staphylococcus spp.
Resistance to dalbavancin in Staphylococcus spp. and Enterococcus spp. is mediated by VanA, a genotype that results in modification of the target peptide in nascent cell wall.
Dermal infections(pyoderma- superficial and deep, wounds, abscesses)caused by susceptible pathogens such as Staphylococcus spp., E. coli and Proteus mirabilis.
Enterobacteriaceae:≤ 4 µg/ mlsusceptible,≥ 32 µg/ ml resistant Staphylococcus spp.:≤ 4 µg/ ml susceptible,≥ 32 µg/ ml resistant Haemophilus spp.:≤ 4 µg/ ml susceptible;≥ 16 µg/ ml resistant Streptococcus pneumoniae:≤ 1 µg/ ml susceptible,≥ 4 µg/ ml resistant Streptococcus spp. other than S. pneumoniae.
Upper respiratory tractinfections caused by susceptible pathogens such as Staphylococcus spp., E. coli, Klebsiella spp. and Pasteurella spp. .
The MIC breakpoints according to the Clinical and LaboratoryStandards Institute formerly National Committee for Clinical Laboratory Standards are 8 µg/ ml(sensitive), 16-32 µg/ ml(intermediate) and 64 µg/ ml(resistant) for Enterobacteriaceae and Staphylococcus spp.
Dermal infections(soft tissue infections- wounds, abscesses)caused by susceptible pathogens such as Staphylococcus spp, E. coli, Proteus spp. and Pasteurella spp. .
The proportion of Staphylococcus spp. and Pseudomonas spp. isolates decreased during storage of MAP(20-100% CO2) ground chicken for 28 days at 2°C, with Lactobacillus as the predominant genus, whereas Pseudomonas spp. accounted for 92-98% of the isolates in air packaged chicken; an anaerobe stated to be C. perfringens was detected from detected from day 14 in 100% CO2 samples and on day 28 in 20-80% CO2 samples 32.
For ibafloxacin(parent compound), MIC values ranging from0.032- 0.5 µg/ ml are observed for canine isolates of E. coli, Staphylococcus spp. and Proteus mirabilis.
Clinical and Laboratory Standards Institute™(CLSI) MIC and disc diffusion breakpoints for Staphylococcus spp. and fastidious organisms(M100-S17, 2007) and MIC breakpoints for anaerobes M11-A7, 2007.
For ibafloxacin(parent compound), MIC values ranging from 0.032-0.5g/ml are observed for canine isolates of E. coli, Staphylococcus spp. and Proteus mirabilis.
Treatment of:• Acute uncomplicated urinarytract infections caused by Escherichia coli or Staphylococcus spp• Superficial pyoderma caused by Staphylococcus intermedius.
Dicural 50 mg/ ml solution for injection is indicated for the treatment of:• Acute uncomplicated urinarytract infections caused by Escherichia coli or Staphylococcus spp• Superficial pyoderma caused by Staphylococcus intermedius.
For the treatment of:• Acute uncomplicated urinarytract infections caused by Escherichia coli or Staphylococcus spp.• Superficial pyoderma caused by Staphylococcus intermedius.
Dicural coated tablets are indicated for the following clinical conditions in dogs:• Acute uncomplicated urinarytract infections caused by Escherichia coli or Staphylococcus spp.• Superficial pyoderma caused by Staphylococcus intermedius.
At 4 times the minimum inhibitory concentration(MIC), a 2-log reduction in colonycounts was observed with tigecycline against Enterococcus spp., Staphylococcus aureus, and Escherichia coli.